Table of Contents

company-logo

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Intra-Cellular Therapies Dividend Announcement

• Intra-Cellular Therapies does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Intra-Cellular Therapies dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Intra-Cellular Therapies Dividend History

Intra-Cellular Therapies Dividend Yield

Intra-Cellular Therapies current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Intra-Cellular Therapies stock? Use our calculator to estimate your expected dividend yield:

Intra-Cellular Therapies Financial Ratios

P/E ratio-112.14
PEG ratio-40.79
P/B ratio8.46
ROE-9.93%
Payout ratio0.00%
Current ratio7.66
Quick ratio7.51
Cash Ratio2.80

Intra-Cellular Therapies Dividend FAQ

Does Intra-Cellular Therapies stock pay dividends?
Intra-Cellular Therapies does not currently pay dividends to its shareholders.
Has Intra-Cellular Therapies ever paid a dividend?
No, Intra-Cellular Therapies has no a history of paying dividends to its shareholders. Intra-Cellular Therapies is not known for its dividend payments.
Why doesn't Intra-Cellular Therapies pay dividends?
There are several potential reasons why Intra-Cellular Therapies would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Intra-Cellular Therapies ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Intra-Cellular Therapies has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Intra-Cellular Therapies a dividend aristocrat?
Intra-Cellular Therapies is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Intra-Cellular Therapies a dividend king?
Intra-Cellular Therapies is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Intra-Cellular Therapies a dividend stock?
No, Intra-Cellular Therapies is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Intra-Cellular Therapies stocks?
To buy Intra-Cellular Therapies you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Intra-Cellular Therapies stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.